BIOMAT Database Logo BIOMAT Database Logo

Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. 1999

J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Department of Nephrology, Hannover Medical School, Germany.

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide (NO) synthase. Its concentration is elevated in patients with end-stage renal disease (ESRD), in part because it is excreted via the kidneys. In this study, the plasma concentrations of ADMA, symmetric dimethylarginine, and L-arginine were determined in relation to plasma nitrate levels (as an index of NO formation) for a group of 80 patients with ESRD. The effects of two treatment methods, i.e., hemodialysis (HD) and peritoneal dialysis (PD), and the role of the presence of atherosclerotic disease were evaluated. Forty-three patients receiving HD and 37 patients receiving PD were compared with healthy control subjects. Plasma L-arginine and dimethylarginine levels were determined by HPLC, using precolumn derivatization with o-phthaldialdehyde. Plasma nitrate levels were determined by gas chromatography-mass spectrometry. Predialysis ADMA concentrations in HD-treated patients were approximately sixfold higher than those in the control group (6.0+/-0.5 versus 1.0+/-0.1 micromol/L; P < 0.05). Plasma nitrate concentrations were significantly lower in HD-treated patients, which suggests that ADMA may inhibit NO synthase. In contrast, plasma ADMA levels and nitrate concentrations in PD-treated patients were similar to those in control subjects. Plasma L-arginine concentrations were not significantly decreased in patients with ESRD. ADMA concentrations were significantly decreased 5 h after HD, compared with baseline values. ADMA levels were significantly higher in HD-treated patients with manifest atherosclerotic disease than in HD-treated patients without atherosclerotic disease (7.31+/-0.70 versus 3.95+/-0.52 micromol/L; P < 0.05). This study confirms that ADMA is accumulated in ESRD. PD-treated patients exhibit significantly lower ADMA levels than do HD-treated patients. Accumulation of ADMA may be a risk factor for the development of endothelial dysfunction and cardiovascular disease in patients with ESRD.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease.
January 2002, Blood purification,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients.
January 2008, Nephron. Clinical practice,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
January 2002, Blood purification,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end‑stage renal disease treated with hemodialysis.
January 2012, Polskie Archiwum Medycyny Wewnetrznej,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?
September 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
The relationship between plasma homocysteine and amino acid concentrations in patients with end-stage renal disease.
January 1998, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.
January 2012, The Journal of international medical research,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.
January 2008, Clinical nephrology,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow.
November 2007, Coronary artery disease,
J T Kielstein, and R H Böger, and S M Bode-Böger, and J Schäffer, and M Barbey, and K M Koch, and J C Frölich
Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.
January 2009, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation,
Copied contents to your clipboard!